Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Inimmune logo — Harnessing the immune system to create next generation immun...

Inimmune

Harnessing the immune system to create next generation immunotherapeutics for the treatment of a wide array of diseases.

Founded 2016 United States Missoula, United States 37 employees Series A Total: $22.60M Biotechnology, Health Care

General Information

Company Name Inimmune
Founded Year 2016
Location United States Missoula, United States
Founders / Decision Makers
Team member Team member
Employees 37
Industries Biotechnology, Health Care
Funding Stage Series A
Business Model B2B, B2B2C
Revenue Model Licensing, Project Based, Performance Based
Social

BounceWatch is an independent company data service, not affiliated with Inimmune. To contact Inimmune, visit inimmune.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Inimmune compare?

A PDF of Inimmune and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Inimmune soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Inimmune

Inimmune, a pioneering biotechnology startup, is making significant strides in the field of healthcare. Founded in 2016 by veterans of the pharmaceutical industry, the company is dedicated to developing next-generation immunotherapeutics designed to harness the immune system for treating a wide array of diseases. With its headquarters in the United States, the startup positions itself at the intersection of the Biotechnology and Health Care industries.

Their mission, encapsulated in their slogan, "Harnessing the immune system to create next generation immunotherapeutics for the treatment of a wide array of diseases," reflects a commitment to innovation and therapeutic advancement. In its growth journey, Inimmune secured a substantial $22.00M Series A investment in July 2020, led by Two Bear Capital. This investment underscores significant confidence from investors, anticipating robust advancements and breakthroughs in their specialized field.

Taxonomy: Immunotherapeutics, Innate Immunity, Pharmaceuticals, Drug Discovery, Medical Research, Cancer Treatment, Autoimmune Diseases, Allergy Treatment, Medical Technology, Biopharmaceuticals

Services & Products

Development of disease-modifying immunotherapies
Innovative vaccine adjuvants
Clinical-stage trials for immunotherapy and vaccines
Collaborative research projects with universities and biotech firms

Target Customers

Patients with allergic rhinitis Healthcare providers focusing on immunotherapy Biopharmaceutical companies Research institutions and universities

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $22.00M 1
Two Bear Capital
Two Bear Capital
01 Jul 2020
Grant $600.00K 1
National Investment Co.
National Investment Co.
01 Oct 2018
Spinout Undisclosed 1
University of Montana
01 Jan 2016

Inimmune Alternatives & Competitors

View All Alternatives
Inimmune vs
United Biomedical, Inc. (UBI)
United Biomedical, Inc. (UBI) United States

Pioneering the future of healthcare with innovative immunotherapeutics and vaccines for chronic and...

44 employees
Biotechnology, Health Care
Inimmune vs
MacroGenics, Inc.
MacroGenics, Inc. United States

Developing immunotherapeutics to prevent autoimmune disorders, cancer and infectious diseases

379 employees
Biotechnology, Health Care
Inimmune vs
Georgiamune Inc.
Georgiamune Inc. United States

Georgiamune is reprogramming immune signaling pathways to redirect the immune system to fight diseas...

Series A
30 employees
Biotechnology, Health Care
View all alternatives

FAQ About Inimmune

Harnessing the immune system to create next generation immunotherapeutics for the treatment of a wide array of diseases.
Inimmune was founded in 2016.
Inimmune is headquartered in Missoula, United States.
Inimmune operates in Biotechnology and Health Care. Its work centres on Immunotherapeutics, Innate Immunity, Pharmaceuticals and Drug Discovery. Its customers include Patients with allergic rhinitis, Healthcare providers focusing on immunotherapy and Biopharmaceutical companies.
Inimmune has a B2B and B2B2C business model. Its revenue comes from Licensing, Project Based and Performance Based.
Inimmune has approximately 37 employees.
Inimmune has completed 3 funding rounds, raising a total of $22.60M. The latest funding stage is Series A.
Inimmune offers: Development of disease-modifying immunotherapies, Innovative vaccine adjuvants, Clinical-stage trials for immunotherapy and vaccines, Collaborative research projects with universities and biotech firms.
Top alternatives and competitors to Inimmune include United Biomedical, Inc. (UBI), MacroGenics, Inc., Georgiamune Inc., 858 Therapeutics, Telormedix. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Inimmune and United Biomedical, Inc. (UBI) are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Inimmune, https://bouncewatch.com/company/inimmune, updated 18 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes